Related references
Note: Only part of the references are listed.Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Charles E. Hendrick et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Orelabrutinib: First Approval
Sohita Dhillon
DRUGS (2021)
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Danling Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Garth E. Ringheim et al.
FRONTIERS IN IMMUNOLOGY (2021)
Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently
Zimo Yang et al.
CELL RESEARCH (2021)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
Albert Liclican et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
Ronen Gabizon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Wen-Hao Guo et al.
NATURE COMMUNICATIONS (2020)
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A. Nalawansha et al.
CELL CHEMICAL BIOLOGY (2020)
A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders
Ka Yang et al.
CELL CHEMICAL BIOLOGY (2020)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction
Xing Qiu et al.
ORGANIC LETTERS (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dennis Dobrovolsky et al.
BLOOD (2019)
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding
Christopher P. Tinworth et al.
ACS CHEMICAL BIOLOGY (2019)
Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders
Mette Ishoey et al.
ACS CHEMICAL BIOLOGY (2018)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
Sean D. Reiff et al.
BLOOD (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Quinlan L. Sievers et al.
SCIENCE (2018)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Target engagement and drug residence time can be observed in living cells with BRET
Matthew B. Robers et al.
NATURE COMMUNICATIONS (2015)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
